Bone loss is common in patients with breast cancer. Bone modifying agents (BMAs), such as bisphosphonates and denosumab, have been shown to reverse or stabilize bone loss and may be useful in the primary and metastatic settings. The purpose of this review is to provide clear evidence-based strategies for the management of bone loss and its symptoms in breast cancer. A systematic review of clinical trials and meta-analyses published between 1996 and 2012 was conducted of MEDLINE and EMBASE. Reference lists were hand-searched for additional publications. Recommendations were developed based on the best available evidence. Zoledronate, pamidronate, clodronate, and denosumab are recommended for metastatic breast cancer patients; however, no one agent can be recommended over another. Zoledronate or any oral bisphosphonate and denosumab should be considered in primary breast cancer patients who are postmenopausal on aromatase inhibitor therapy and have a high risk of fracture and/or a low bone mineral density and in premenopausal primary breast cancer patients who become amenorrheic after therapy. No one agent can be recommended over another. BMAs are not currently recommended as adjuvant therapy in primary breast cancer for the purpose of improving survival, although a major Early Breast Cancer Cooperative Trialists’ Group meta-analysis is underway which may impact future practice. Adverse events can be managed with appropriate supportive care.
References
[1]
Perez, E.A. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann. Oncol. 2007, 18, 26–35.
[2]
Robbins, J.; Aragaki, A.K.; Kooperberg, C.; Watts, N.; Wactawski-Wende, J.; Jackson, R.D.; LeBoff, M.S.; Lewis, C.E.; Chen, Z.; Stefanick, M.L.; et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA 2007, 298, 2389–2398, doi:10.1001/jama.298.20.2389.
[3]
Kanis, J.A.; Powles, T.; Paterson, A.H.; McCloskey, E.V.; Ashley, S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996, 19, 663–667, doi:10.1016/S8756-3282(96)00285-2.
Paterson, A.; McCloskey, E.; Redzepovic, J.; Ott, I.; Gust, R. Cost effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate, or intravenous pamidronate in breast cancer patients. J. Int. Med. Res. 2008, 36, 400–413, doi:10.1177/147323000803600304.
[6]
Coleman, R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer. Res. 2006, 12, 6243–6249, doi:10.1158/1078-0432.CCR-06-0931.
[7]
National Institute for Health and Clinical Excellence. How NICE Clinical Guidelines are Developed: An Overview for Stakeholders, the Public and the NHS, 4th ed. ed.; National Institute for Health and Clinical Excellence: London, UK, 2009.
AGREE Collaboration. Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument. Available online: http://www.agreetrust.org/ (accessed on 15 November 2009).
[10]
Hillner, B.E.; Ingle, J.N.; Chlebowski, R.T.; Gralow, J.; Yee, G.C.; Janjan, N.A.; Cauley, J.A.; Blumenstein, B.A.; Albain, K.S.; Lipton, A.; et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 2003, 21, 4042–4057, doi:10.1200/JCO.2003.08.017.
[11]
Van Poznak, C.H.; Temin, S.; Yee, G.C.; Janjan, N.A.; Barlow, W.E.; Biermann, J.S.; Bosserman, L.D.; Geoghegan, C.; Hillner, B.E.; Theriault, R.L.; et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J. Clin. Oncol. 2011, 29, 1221–1227, doi:10.1200/JCO.2010.32.5209.
[12]
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, v.2.2010. Available online: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf (accessed on 1 December 2010).
[13]
Warr, D.; Johnston, M.; Members of the Breast Cancer Disease Site Group. Use of Bisphosphonates in Women with Breast Cancer. Practice Guideline. Available online: http://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc1–11f.pdf (accessed on 15 November 2009).
[14]
British Columbia Cancer Agency. Cancer Management Guidelines, Breast, 2006. Available online: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Breast/Management/MetastaticDisease.htm (accessed on 15 September 2010).
[15]
Body, J.J.; Coleman, R.; Clezardin, P.; Ripamonti, C.; Rizzoli, R.; Aapro, M. International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur. J. Cancer 2007, 43, 852–858, doi:10.1016/j.ejca.2006.12.006.
[16]
De Marinis, F.; Eberhardt, W.; Harper, P.G.; Massuti Sureda, B.; Nackaerts, K.; Benn Soerensen, J.; Syrigos, K.; Tredaniel, J. Bisphosphonate use in patients with lung cancer and bone metastases: Recommendations of a European Expert Panel. J. Thorac. Oncol. 2009, 4, 1280–1288, doi:10.1097/JTO.0b013e3181b68e5a.
[17]
Cancer Care Australia, National Breast and Ovarian Cancer Centre. Recommendations for Use of Bisphosphonates for Advanced Breast Cancer. Available online: http://guidelines.nbocc.org.au/guidelines/bisphosphonates_advanced/ (accessed on 15 September 2010).
[18]
Kuchuk, I.; Paterson, A.; Amir, E.; Clemons, M.; Bouganim, N. Treatment recommendations for the use of bone-targeted agents in 2011—Report from the 6th Annual Bone and the Oncologist New Updates (BONUS 6) meeting. Curr. Oncol. 2012, 19, 364–370.
[19]
World Health Organization Collaborating Centre for Metabolic Bone Diseases. WHO Fracture Risk Assessment Tool. University of Sheffield: Sheffield, UK. Available online: http://www.shef.ac.uk/FRAX/ (accessed on 1 December 2012).
[20]
Safra, T.; Bernstein-Molho, R.; Greenberg, J.; Pelles-Avraham, S.; Stephansky, I.; Sarid, D.; Inbar, M.J.; Stemmer, S.M.; Geffen, D. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: A prospective, randomized, phase II trial. Oncology 2011, 81, 298–305, doi:10.1159/000334456.
[21]
Van Poznak, C.; Hannon, R.A.; Mackey, J.R.; Campone, M.; Apffelstaedt, J.P.; Clack, G.; Barlow, D.; Makris, A.; Eastell, R. Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J. Clin. Oncol. 2010, 28, 967–975, doi:10.1200/JCO.2009.24.5902.
[22]
Hines, S.L.; Sloan, J.A.; Atherton, P.J.; Perez, E.A.; Dakhil, S.R.; Johnson, D.B.; Reddy, P.S.; Dalton, R.J.; Mattar, B.I.; Loprinzi, C.L. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast 2010, 19, 92–96, doi:10.1016/j.breast.2009.12.001.
[23]
Ellis, G.K.; Bone, H.G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Fan, M.; Kim, D. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: Subgroup analyses of a phase 3 study. Breast Cancer Res. Treat. 2009, 118, 81–87, doi:10.1007/s10549-009-0352-y.
[24]
Ellis, G.K.; Bone, H.G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Smith, J.; Fan, M.; Jun, S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 2008, 26, 4875–4882, doi:10.1200/JCO.2008.16.3832.
[25]
Hines, S.L.; Mincey, B.A.; Sloan, J.A.; Thomas, S.P.; Chottiner, E.; Loprinzi, C.L.; Carlson, M.D.; Atherton, P.J.; Salim, M.; Perez, E.A. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J. Clin. Oncol. 2009, 27, 1047–1053, doi:10.1200/JCO.2008.19.1783.
[26]
Cohen, A.; Fleischer, J.B.; Johnson, M.K.; Brown, I.N.; Joe, A.K.; Hershman, D.L.; Hershman, D.L.; McMahon, D.J.; Silverberg, S.J. Prevention of bone loss after withdrawal of tamoxifen. Endocr. Pract. 2008, 14, 162–167, doi:10.4158/EP.14.2.162.
[27]
Lester, J.E.; Dodwell, D.; Purohit, O.P.; Gutcher, S.A.; Ellis, S.P.; Thorpe, R.; Horsman, J.M.; Brown, J.E.; Hannon, R.A.; Coleman, R.E. Prevention of anastrazole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res. 2008, 14, 6336–6342, doi:10.1158/1078-0432.CCR-07-5101.
[28]
Kim, J.E.; Ahn, J.H.; Jung, K.H.; Kim, S.B.; Kim, H.J.; Lee, K.S.; Ro, J.S.; Park, Y.H.; Ahn, J.S.; Im, Y.H.; et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: A phase III study of Korean cancer study group (KCSG-BR06-01). Breast Cancer Res. Treat. 2011, 125, 99–106.
[29]
McCloskey, E.; Paterson, A.; Kanis, J.; Tahtela, R.; Powles, T. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur. J. Cancer 2010, 46, 558–565, doi:10.1016/j.ejca.2009.12.003.
[30]
Hershman, D.L.; McMahon, D.J.; Crew, K.D.; Shao, T.; Cremers, S.; Brafman, L.; Awad, D.; Shane, E. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J. Clin. Endocrinol. Metab. 2010, 95, 559–566, doi:10.1210/jc.2009-1366.
[31]
Hershman, D.L.; McMahon, D.J.; Crew, K.D.; Cremers, S.; Irani, D.; Cucchiara, G.; Brafman, L.; Shane, E. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J. Clin. Oncol. 2008, 26, 4739–4745, doi:10.1200/JCO.2008.16.4707.
[32]
Greenspan, S.L.; Bhattacharya, R.K.; Sereika, S.M.; Brufsky, A.; Vogel, V.G. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 2007, 92, 131–136.
[33]
Greenspan, S.L.; Brufsky, A.; Lembersky, B.C.; Bhattacharya, R.; Vujevich, K.T.; Perera, S.; Sereika, S.M.; Vogel, V.G. Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blind, placebo-controlled clinical trial. J. Clin. Oncol. 2008, 26, 2644–2652, doi:10.1200/JCO.2007.15.2967.
[34]
Fuleihan, G.-H.; Salamoun, M.; Mourad, Y.A.; Chehal, A.; Salem, Z.; Mahfoud, Z.; Shamseddine, A. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: A randomized controlled trial. J. Clin. Endocrinol. Metab. 2005, 90, 3209–3214, doi:10.1210/jc.2004-1444.
[35]
Delmas, P.D.; Balena, R.; Confravreux, E.; Hardouin, C.; Hardy, P.; Bremond, A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J. Clin. Oncol. 1997, 15, 955–962.
[36]
Saarto, T.; Vehmanen, L.; Blomqvist, C.; Elomaa, I. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J. Clin. Oncol. 2008, 26, 4289–4295, doi:10.1200/JCO.2007.15.4997.
[37]
Saarto, T.; Taube, T.; Blomqvist, C.; Vehmanen, L.; Elomaa, I. Three-year oral clodronate treatment does not impair mineralization of newly formed bone—A histomorphometric study. Calcif. Tissue Int. 2005, 77, 84–90, doi:10.1007/s00223-004-0262-2.
[38]
Brufsky, A.M.; Bosserman, L.D.; Caradonna, R.R.; Haley, B.B.; Jones, C.M.; Moore, H.C.; Jin, L.; Warsi, G.M.; Ericson, S.G.; Perez, E.A. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin. Breast Cancer 2009, 9, 77–85, doi:10.3816/CBC.2009.n.015.
[39]
Brufsky, A.; Harker, W.G.; Beck, J.T.; Carroll, R.; Tan-Chiu, E.; Seidler, C.; Hohneker, J.; Lacerna, L.; Petrone, S.; Perez, E.A. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol. 2007, 25, 829–836, doi:10.1200/JCO.2005.05.3744.
[40]
Brufsky, A.M.; Harker, W.G.; Beck, J.T.; Bosserman, L.; Vogel, C.; Seidler, C.; Jin, L.; Warsi, G.; Argonza-Aviles, E.; Hohneker, J.; et al. Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012, 118, 1192–1201, doi:10.1002/cncr.26313.
[41]
Brufsky, A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin. Oncol. 2006, 33, 13–17, doi:10.1053/j.seminoncol.2006.03.022.
[42]
Bundred, N.J.; Campbell, I.D.; Davidson, N.; DeBoer, R.H.; Eidtmann, H.; Monnier, A.; Neven, P.; von Minckwitz, G.; Miller, J.C.; Schenk, N.L.; et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008, 112, 1001–1010, doi:10.1002/cncr.23259.
[43]
Eidtmann, H.; de Boer, R.; Bundred, N.; Llombart-Cussac, A.; Davidson, N.; Neven, P.; von Minckwitz, G.; Miller, J.; Schenk, N.; Coleman, R. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-Month results of the ZO-FAST study. Ann. Oncol. 2010, 21, 2188–2194, doi:10.1093/annonc/mdq217.
[44]
Logman, J.F.; Heeg, B.M.; Botteman, M.F.; Kaura, S.; van Hout, B.A. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Ann. Oncol. 2010, 21, 1529–1536, doi:10.1093/annonc/mdp560.
[45]
Brufsky, A.; Bundred, N.; Coleman, R.; Lambert-Falls, R.; Mena, R.; Hadji, P.; Jin, L.; Schenk, N.; Ericson, S.; Perez, E.A.; Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13, 503–514, doi:10.1634/theoncologist.2007-0206.
[46]
Coleman, R.; de Boer, R.; Eidtmann, H.; Llombart, A.; Davidson, N.; Neven, P.; von Minckwitz, G.; Sleeboom, H.P.; Forbes, J.; Barrios, C.; et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann. Oncol. 2013, 24, 398–405, doi:10.1093/annonc/mds277.
[47]
Llombart, A.; Frassoldati, A.; Paija, O.; Sleeboom, H.P.; Jerusalem, G.; Mebis, J.; Deleu, I.; Miller, J.; Schenk, N.; Neven, P. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-Month analysis of the E-ZO-FAST trial. Clin. Breast Cancer 2012, 12, 40–48, doi:10.1016/j.clbc.2011.08.002.
[48]
Hines, S.L.; Mincey, B.; Dentchev, T.; Sloan, J.A.; Perez, E.A.; Johnson, D.B.; Schaefer, P.L.; Alberts, S.; Liu, H.; Kahanic, S.; et al. Immediate vs. delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res. Treat. 2009, 117, 603–609, doi:10.1007/s10549-009-0332-2.
[49]
Body, J.J.; Lipton, A.; Gralow, J.; Steger, G.G.; Gao, G.; Yeh, H.; Fizazi, K. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J. Bone Miner. Res. 2010, 25, 440–446, doi:10.1359/jbmr.090810.
[50]
Stopeck, A.T.; Lipton, A.; Body, J.J.; Steger, G.G.; Tonkin, K.; de Boer, R.H.; Lichinitser, M.; Fujiwara, Y.; Yardley, D.A.; Viniegra, M.; et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 2010, 28, 5132–5139, doi:10.1200/JCO.2010.29.7101.
[51]
Body, J.J.; Lichinitser, M.R.; Tjulandin, S.; Garnero, P.; Bergstr？m, B. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann. Oncol. 2007, 18, 1165–1171, doi:10.1093/annonc/mdm119.
[52]
Kohno, N.; Aogi, K.; Minami, H.; Nakamura, S.; Asaga, T.; Iino, Y.; Watanabe, T.; Goessl, C.; Ohashi, Y.; Takashima, S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J. Clin. Oncol. 2005, 23, 3314–3321, doi:10.1200/JCO.2005.05.116.
[53]
Tripathy, D.; Lichinitzer, M.; Lazarev, A.; MacLachlan, S.A.; Apffelstaedt, J.; Budde, M.; Bergstrom, B.; MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann. Oncol. 2004, 15, 743–750, doi:10.1093/annonc/mdh173.
[54]
Rosen, L.S.; Gordon, D.H.; Dugan, W., Jr.; Major, P.; Eisenberg, P.D.; Provencher, L.; Kaminski, M.; Simeone, J.; Seaman, J.; Chen, B.L.; et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004, 100, 36–43, doi:10.1002/cncr.11892.
[55]
Body, J.J.; Diel, I.J.; Bell, R.; Pecherstorfer, M.; Lichinitser, M.R.; Lazarev, A.F.; Tripathy, D.; Bergstr？m, B. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004, 111, 306–312, doi:10.1016/j.pain.2004.07.011.
[56]
Lipton, A.; Theriault, R.L.; Hortobagyi, G.N.; Simeone, J.; Knight, R.D.; Mellars, K.; Reitsma, D.J.; Heffernan, M.; Seaman, J.J. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88, 1082–1090, doi:10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z.
[57]
Kristensen, B.; Ejlertsen, B.; Groenvold, M.; Hein, S.; Loft, H.; Mouridsen, H.T. Oral clodronate in breast cancer patients with bone metastases: A randomized study. Intern. Med. 1999, 246, 67–74, doi:10.1046/j.1365-2796.1999.00507.x.
[58]
Theriault, R.L.; Lipton, A.; Hortobagyi, G.N.; Leff, R.; Glück, S.; Stewart, J.F.; Costello, S.; Kennedy, I.; Simeone, J.; Seaman, J.J.; et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. J. Clin. Oncol. 1999, 17, 846–854.
[59]
Hortobagyi, G.N.; Theriault, R.L.; Lipton, A.; Porter, L.; Blayney, D.; Sinoff, C.; Wheeler, H.; Simeone, J.F.; Seaman, J.J.; Knight, R.D.; et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 1998, 16, 2038–2044.
[60]
Conte, P.F.; Latreille, J.; Mauriac, L.; Calabresi, F.; Santos, R.; Campos, D.; Bonneterre, J.; Francini, G.; Ford, J.M. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. J. Clin. Oncol. 1996, 14, 2552–2559.
[61]
Paterson, A.H.G.; Powles, T.J.; Kanis, J.A.; McCloskey, E.; Hanson, J.; Ashley, S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 1993, 11, 59–65.
[62]
Paterson, A.H.; Anderson, S.J.; Lembersky, B.C.; Fehrenbacher, L.; Falkson, C.I.; King, K.M.; Weir, L.M.; Brufsky, A.M.; Dakhil, S.; Lad, T.; et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012, 13, 734–742, doi:10.1016/S1470-2045(12)70226-7.
[63]
Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; P？stlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 2009, 360, 679–691, doi:10.1056/NEJMoa0806285.
[64]
Gnant, M.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Kainberger, F.; K？ssmann, H.; Piswanger-S？lkner, J.C.; Seifert, M.; Ploner, F.; Menzel, C.; Fitzal, F.; et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-Year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008, 9, 840–849, doi:10.1016/S1470-2045(08)70204-3.
[65]
Gnant, M.; Mlineritsch, B.; Stoeger, H.; Luschin-Ebengreuth, G.; Heck, D.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Pristauz, G.; et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-Month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011, 12, 631–641, doi:10.1016/S1470-2045(11)70122-X.
[66]
Gnant, M.F.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Grampp, S.; Kaessmann, H.; Schmid, M.; Menzel, C.; Piswanger-Soelkner, J.C.; Galid, A.; Mittlboeck, M.; et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 2007, 25, 820–828, doi:10.1200/JCO.2005.02.7102.
[67]
Coleman, R.E.; Winter, M.C.; Cameron, D.; Bell, R.; Dodwell, D.; Keane, M.M.; Gil, M.; Ritchie, D.; Passos-Coelho, J.L.; Wheatley, D.; et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer 2010, 102, 1099–1105, doi:10.1038/sj.bjc.6605604.
[68]
Coleman, R.E.; Marshall, H.; Cameron, D.; Dodwell, D.; Burkinshaw, R.; Keane, M.; Gil, M.; Houston, S.J.; Grieve, R.J.; Barrett-Lee, P.J.; et al. Breast-cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 2011, 365, 1396–1405, doi:10.1056/NEJMoa1105195.
[69]
Aft, R.; Naughton, M.; Trinkaus, K.; Watson, M.; Ylagan, L.; Chavez-MacGregor, M.; Zhai, J.; Kuo, S.; Shannon, W.; Diemer, K.; et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial. Lancet Oncol. 2010, 11, 421–428, doi:10.1016/S1470-2045(10)70054-1.
[70]
Kristensen, B.; Ejlertsen, B.; Mouridsen, H.T.; Jensen, M.B.; Andersen, J.; Bjerregaard, B.; Cold, S.; Edlund, P.; Ewertz, M.; Kamby, C.; et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate vs. no pamidronate in patients with primary breast cancer. Acta Oncol. 2008, 47, 740–746, doi:10.1080/02841860801964988.
[71]
Diel, I.J.; Jaschke, A.; Solomayer, E.F.; Gollan, C.; Bastert, G.; Sohn, C.; Schuetz, F. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: A long-term follow-up. Ann. Oncol. 2008, 19, 2007–2011, doi:10.1093/annonc/mdn429.
[72]
Diel, I.J.; Solomayer, E.F.; Costa, S.D.; Gollan, C.; Goerner, R.; Wallwiener, D.; Kaufmann, M.; Bastert, G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 1998, 339, 357–363, doi:10.1056/NEJM199808063390601.
[73]
Powles, T.; Paterson, S.; Kanis, J.A.; McCloskey, E.; Ashley, S.; Tidy, A.; Rosenqvist, K.; Smith, I.; Ottestad, L.; Legault, S.; et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. 2002, 20, 3219–3224, doi:10.1200/JCO.2002.11.080.
[74]
Powles, T.J.; McCloskey, E.; Paterson, A.H.; Ashley, S.; Tidy, A.; Rosenqvist, K.; Smith, I.; Ottestad, L.; Legault, S.; Pajunen, M.; et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J. Natl. Cancer Inst. 1998, 90, 704–708, doi:10.1093/jnci/90.9.704.
[75]
Saarto, T.; Vehmanen, L.; Virkkunen, P.; Blomqvist, C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004, 43, 650–656, doi:10.1080/02841860410032885.
[76]
Saarto, T.; Blomqvist, C.; Virkkunen, P.; Elomaa, I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trial. J. Clin. Oncol. 2001, 19, 10–17.
[77]
Fox, K.R. Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: A new care standard or a provocative idea? Curr. Oncol. Rep. 2010, 12, 1–3, doi:10.1007/s11912-009-0074-7.
[78]
Hamdy, N.A. Denosumab: RANKL inhibition in the management of bone loss. Drugs Today (Barc.) 2008, 44, 7–21, doi:10.1358/dot.2008.44.1.1178467.
[79]
U. S. Food and Drug Administration. Approval Package for: Application Number NDA 21817/S-012. Center for Drug Evaluation and Research. Available online: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021817Orig1s012.pdf (accessed on 21 November 2013).
[80]
Amgen, M.D. Study of Denosumab as Adjuvant Treatment for Women with High Risk Early Breast Cancer Receiving Neo-adjuvant or Adjuvant Therapy (D-CARE). Available online: http://www.ClinicalTrials.gov (accessed on 14 February 2013).
[81]
Lipton, A.; Steger, G.G.; Figueroa, J.; Alvarado, C.; Solal-Celigny, P.; Body, J.J.; de Boer, R.; Berardi, R.; Gascon, P.; Tonkin, K.S.; et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin. Cancer Res. 2008, 14, 6690–6696, doi:10.1158/1078-0432.CCR-07-5234.
[82]
Hirschberg, R. Renal complications from bisphosphonate treatment. Curr. Opin. Support. Palliat. Care 2012, 6, 342–347, doi:10.1097/SPC.0b013e328356062e.
[83]
Yilmaz, M.; Taninmis, H.; Kara, E.; Ozagari, A.; Unsal, A. Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis. Osteoporos. Int. 2012, 23, 2059–2062, doi:10.1007/s00198-011-1836-2.
[84]
Miller, P.D.; Ragi-Eis, S.; Mautalen, C.; Ramirez, F.; Jonkanski, I. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease—The DIVINE study. Bone 2011, 49, 1317–1322, doi:10.1016/j.bone.2011.09.035.
[85]
Biggar, P.H.; Liangos, O.; Fey, H.; Brandenburg, V.M.; Ketteler, M. Vitamin D, chronic kidney disease and survival: A pluripotent hormone or just another bone drug? Pediatr. Nephrol. 2011, 26, 7–18, doi:10.1007/s00467-010-1526-x.
[86]
Yamazaki, T.; Yamori, M.; Ishizaki, T.; Asai, K.; Goto, K.; Takahashi, K.; Nakayama, T.; Bessho, K. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: A cohort study. Int. J. Oral Maxillofac. Surg. 2012, 41, 1397–1403, doi:10.1016/j.ijom.2012.06.020.
[87]
Petcu, E.B.; Ivanovski, S.; Wright, R.G.; Slevin, M.; Miroiu, R.I.; Brinzaniuc, K. Bisphosphonate-related osteonecrosis of jaw (BRONJ): An anti-angiogenic side-effect? Diagn. Pathol. 2012, 7, 78, doi:10.1186/1746-1596-7-78.
[88]
Amadori, D.; Aglietta, M.; Alessi, B.; Gianni, L.; Ibrahim, T.; Farina, G.; Gaion, F.; Bertoldo, F.; Santini, D.; Rondena, R.; et al. Efficacy and safety of 12-weekly vs. 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol. 2013, 14, 663–670, doi:10.1016/S1470-2045(13)70174-8.
[89]
Shane, E.; Burr, D.; Abrahamsen, B.; Adler, R.A.; Brown, T.D.; Cheung, A.M.; Cosman, F.; Curtis, J.R.; Dell, R.; Dempster, D.W.; et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 2013, doi:10.1002/jbmr.1998.
[90]
Shkolnikova, J.; Flynn, J.; Choong, P. Burden of bisphosphonate-associated femoral fractures. ANZ J. Surg. 2013, 83, 175–181, doi:10.1111/ans.12018.
[91]
Papaioannou, A.; Morin, S.; Cheung, A.M.; Atkinson, S.; Brown, J.P.; Feldman, S.; Hanley, D.A.; Hodsman, A.; Jamal, S.A.; Kaiser, S.M.; et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. Can. Med. Assoc. J. 2010, 182, 1864–1873, doi:10.1503/cmaj.100771.
